New Antibiotic Class Is Aim Of Evotec R&D Pact With Nosopharm
Executive Summary
Evotec and Nosopharm plan to develop and then test in humans the first novel antibiotic class for fighting Gram-negative Enterobacteriaceae infections in 40 years
You may also be interested in...
Deal Watch: Genentech Inks New Collaborations With Skyhawk, Convelo
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
ConserV Says Its Vaccine R&D Is 'Aimed At The Next Pandemic’
ConserV CEO tells Scrip why the late-stage vaccine developer has entered an mRNA development pact with eTheRNA of Belgium and about the UK biotech’s hopes for finding a universal jab against the entire coronavirus family.
Arena Cannabinoid Pain Compound Misses In Phase IIb IBS Trial
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.
Need a specific report? 1000+ reports available
Buy Reports